Roquefort Therapeutics (LON:ROQ) Trading Down 15.2% – Here’s What Happened

Roquefort Therapeutics plc (LON:ROQ) was down 15.2% on Tuesday . The company traded as low as GBX 1.48 ($0.02) and last traded at GBX 1.60 ($0.02). Approximately 6,200,585 shares were traded during trading, an increase of 221% from the average daily volume of 1,934,276 shares. The stock had previously closed at GBX 1.89 ($0.02).

Roquefort Therapeutics Price Performance

The business’s 50 day moving average is GBX 3.12 and its two-hundred day moving average is GBX 3.69. The firm has a market cap of £2.07 million, a P/E ratio of -1.34 and a beta of 0.05. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37.

Insider Buying and Selling

In related news, insider Stephen Paul West purchased 400,000 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was purchased at an average cost of GBX 3 ($0.04) per share, with a total value of £12,000 ($15,467.90). 60.40% of the stock is owned by insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.